Nuvaring (Ethinylestradiol, Etonogestrel)

Ethinylestradiol, the active ingredient in Nuvaring, is a combined hormonal contraceptive presented as a vaginal ring that releases 0.015 mg/day ethinylestradiol and 0.12 mg/day etonogestrel for vaginal use. It prevents pregnancy in women of reproductive age by suppressing ovulation and modifying cervical mucus and the endometrial lining.

GNH USA supplies Nuvaring as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable access to this contraceptive device across global markets.

Nuvaring, a combined hormonal contraceptive, is indicated for prevention of pregnancy.

Contraception: Prevents pregnancy by inhibiting ovulation and altering cervical mucus and endometrial lining. Family planning: Offers a reversible, user‑controlled method of birth control for women seeking long‑term protection. Birth control: Reduces the risk of unintended pregnancy during regular sexual activity.

Nuvaring may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Nausea - Headache - Vaginal irritation or discharge - Breast tenderness - Spotting between periods

Serious or Rare Side Effects: - Deep vein thrombosis or pulmonary embolism - Severe allergic reaction (anaphylaxis) - Hepatic dysfunction or jaundice

Before prescribing Nuvaring, clinicians should evaluate several safety considerations.

Medical history: Assess for personal or family history of thromboembolic disorders. Smoking status: Avoid use in women over 35 who smoke. Medication review: Identify concomitant drugs that may reduce contraceptive efficacy. Pregnancy status: Contraindicated in pregnancy; confirm negative test before initiation. Breastfeeding: Not recommended during lactation. Store at room temperature: Keep in original packaging, protect from moisture and direct sunlight.

Nuvaring can interact with other medicines, affecting its effectiveness or safety.

Major Interactions (Avoid): - Enzyme‑inducing antiepileptics (e.g., carbamazepine, phenytoin) – may markedly reduce hormone levels. - Certain antiretrovirals (e.g., efavirenz) – can decrease contraceptive efficacy. - Strong antifungal agents (e.g., ketoconazole) – may increase hormone concentrations and risk of side effects.

Moderate Interactions (Monitor Closely): - Rifampin and other potent antibiotics – may lower effectiveness of the ring. - Herbal supplements such as St. John’s wort – can accelerate hormone metabolism.